Investigation of the mechanism of lifestyle-related diseases through the functional analysis of Semaphorin 3G, with the goal of developing a novel biomarker.
| Project/Area Number |
23591297
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Metabolomics
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
TAKEMOTO Minoru 千葉大学, 医学(系)研究科(研究院), 准教授 (60447307)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOKOTE Koutaro 千葉大学, 大学院医学研究院, 教授 (20312944)
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | Semaphorin3g / 心腎連関 / 糖代謝 / 生活習慣病 / 糖尿病 / 動脈硬化 / 腎臓病 / セマフォリン / α細胞 |
|---|
| Outline of Final Research Achievements |
The purpose of this study was to investigate the mechanism of lifestyle-related diseases, such as glucose dysregulation, atherosclerosis, and kidney diseases, through the functional analysis of Sema3G, with the goal of developing a novel biomarker.
First, we found that Sema3G had a role in sympathetic nerve navigation and correct positioning to the islets of Langerhans. We also found that Sema3G not only had a role in development of atherosclerosis, but also inhibited inflammation within kidney glomeruli. Through our data, we surmise that Sema3G could be an important factor for lifestyle-related diseases through the modulation of glucose dysregulation, atherosclerosis, and kidney diseases.
|
Report
(5 results)
Research Products
(100 results)
-
-
[Journal Article] Pituitary adenylate cyclase-activating polypeptide protects glomerular podocytes from inflammatory injuries2015
Author(s)
Sakamoto S, Kuno K, Takemoto M, He P, Ishikawa T, Onishi S, Ishibashi R, Yamaga M, Kobayashi K, Kawamura H, Tokuyama H, Maezawa Y, Yokote K
-
Journal Title
Related Report
Peer Reviewed
-
-
-
[Journal Article] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (SUCCESS-1): a multicenter, randomized, open-label, non-inferiority trial.2015
Author(s)
Yokoh H, Kobayashi K, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K; SUCCESS Study Group
-
Journal Title
Journal of Diabetes Invest
Volume: 6(2)
Issue: 2
Pages: 182-191
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
[Journal Article] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with T2DM inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.2014
Author(s)
Kobayashi K, Yokoh H, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S,Yokote K, on behalf of the SUCCESS Study Group.
-
Journal Title
Diabetes, Obesity and Metabolism
Volume: -
Issue: 8
Pages: 761-765
DOI
Related Report
Peer Reviewed
-
[Journal Article] Importance of high-density lipoprotein cholesterol levels in elderly diabetic individuals with type IIb dyslipidemia: A 2-year survey of cardiovascular events.2013
Author(s)
Ina K, Hayashi T, Araki A, Kawashima S, Sone H, Watanabe H, Ohrui T, Yokote K, Takemoto M, Kubota K, Noda M, Noto H, Ding QF, Zhang J, Yu ZY, Yoon BK, Nomura H, Kuzuya M; Japan CDM Group
-
Journal Title
Geriatr Gerontol Int
Volume: 印刷中
Issue: 4
Pages: 806-10
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Sitagliptin Improves Postprandial Hyperglycemia by Inhibiting Glucagon Secretion in Werner Syndrom With Diabetes.2013
Author(s)
Watanabe K, Kobayashi K, Takemoto M, Ishibashi R, Yamaga M, Kawamura H, Fujimoto M, Ishikawa T, Ohnishi S, Okabe E, Peng He, Yokote K.
-
Journal Title
Diabetes Care
Volume: ‐
Issue: 8
Pages: e119-e119
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Metabplic predictions of ischemic heart disease and cerebrovascular attack in elderly diabetic individuals: difference in risk by age.2013
Author(s)
Hayashi T, Araki A, Kawashima S, Sone H, Watanabe H, Ohrui T, Yokote K, Takemoto M, Kubota K, Noda M, Noto H, Ina K, Nomura H; Japan CDM group
-
Journal Title
Cardiovasc Diabetol
Volume: -
Issue: 1
Pages: 10-10
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Angiotensin II Type 1 Receptor Blocker Prevents Renal Injury via Inhibition of the Notch Pathway in Ins2 Akita Diabetic Mice2012
Author(s)
Koshizaka M, Takemoto M, Sato S, Tokuyama H, Fujimoto M, Okabe E, Ishibashi R, Ishikawa T, Tsurutani Y, Onishi S, Mezawa M, He P, Honjo S, Ueda S, Saito Y, Yokote K
-
Journal Title
Exp Diabetes Res
Volume: 1
Pages: 159874-159874
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
